Business

Mangrove Partners, which holds approximately %5.7 of the outstanding shares of CPEX Pharmaceuticals, has announced that it will oppose the merger of CPEX with FCB, a wholly-owned subsidiary of Footstar Corporation. The merger was announced… Read more . . .

Since October 1, 2010, Vectura’s financial performance has exceeded the board’s expectations, according to the company’s interim management statement. Chief Executive Chris Blackwell attributes the improved performance to a restructured R&D program and says that… Read more . . .

North Carolina specialty pharma company Inspire Pharmaceuticals has announced that it is cutting 27% of its workforce (65 jobs) after its denufosol inhalation solution for the treatment of cystic fibrosis failed a Phase 3 trial.… Read more . . .

A group of investors led by LSP Life Sciences Partners of Amsterdam has put together €5 million that device company Activaero will use for continued development of its inhalation systems. Activaero recently initiated clinical studies… Read more . . .

According to MannKind Corporation, it remains committed to gaining approval for its Afrezza inhaled insulin despite continuing requests from the FDA for additional data. The company announced that it is restructuring in order to focus… Read more . . .

According to Teva, its worldwide sales of respiratory drugs, including the Pro-Air albuterol and QVAR beclomethasone inhalers, were down 3% from 2009, to $875 million. Of that amount, $556 million is attributable to sales in… Read more . . .

Isis Pharmaceuticals has reportedly closed down Altair Therapeutics, which it had spun off in 2007 to develop AIR645, an inhaled IL-4 and IL-13 inhibitor for the treatment of asthma. The drug, which was the only… Read more . . .

Assuming that MAP Pharmaceuticals’ Levadex inhaled dihydroergotamine for the treatment of migraine receives FDA approval, Allergan will market the product to pain specialists and neurologists in the US. MAP will handle marketing to primary care… Read more . . .